Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial 131I dose and outcomes in high-risk differentiated thyroid cancer with low postoperative thyroglobulin
ChiCTR2400081902Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iodine-131 in well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Relapse-free survival. Started Mar 2024; status: recruiting.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2400081902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081902.